Company Overview and News

2
Laramide to acquire uranium asset from Rio Tinto

2018-07-17 australianmining.com.au
Canadian uranium company Laramide Resources has made a deal with Rio Tinto to buy the Murphy uranium tenements in the Northern Territory.
LMRXF RTPPF LAM RIO RIO RIO RTNTF LAM

69
Uranium Mining: The Competitive Landscape

2018-06-25 seekingalpha
The operators in the Athabasca Basin, Canada, enjoy the highest-grade uranium deposits and have a geological edge over other uranium districts.
PALAY PEN RIO LAM BLT AZZ TOEYF SYH PDN UEXCF PALAF NXE UEC EFR BMN LMRXF FSY DNN PWURF CVV RIO BBL GVXXF BHPLF FCU SYHBF DYLLF RIO NXGEF BKY ISENF CVVUF WSTRF RTPPF FOSYF TOE RTNTF CCJ UUUU DYL PENMF UWEFF KVLQF TGRUF MGAFF PDN BHPBF FCUUF EU URG DML BKY MGA PUMGF BHP BNNLF 9888 BHP LAM

0
Global Atomic Files Letter to Shareholders, Highlights Company’s Strong Performance Under Current Management and Incumbent Board

2018-06-01 globenewswire
TORONTO, June 01, 2018 (GLOBE NEWSWIRE) -- Global Atomic Corporation (“Global Atomic” or the “Company”), (TSX-V:GLO) today filed on SEDAR a letter to shareholders ahead of its annual and special meeting of shareholders to be held on June 20, 2018.
LMRXF EXGYF HRT SYHBF FSY HRTFF KVLQF LAM VEGYF PWURF PRPCF AZZ SYIFD SYH FOSYF LAM

5
Westwater Resources Reports First Quarter 2018 Operating Results

2018-05-14 globenewswire
CENTENNIAL, Colo., May 14, 2018 (GLOBE NEWSWIRE) -- Westwater Resources, Inc. (Nasdaq:WWR), an energy materials development company, announced today its results for the first quarter of fiscal year 2018, and also discussed its business outlook and its energy materials business development in 2018.
LMRXF URRE URA LAM ABGPF URI ALP WWR LAM URLNF

Related Articles

BLDP: Ballard Power Systems Analysis and Research Report

2018-08-13 - Asif

Core Business At Ballard, Ballard Power Systems is building a clean energy growth company. Ballard Power Systems is recognized as a world leader in proton exchange membrane (“PEM”) fuel cell power system development and commercialization. The company's principal business is the design, development, manufacture, sale and service of PEM fuel cell products for a variety of applications, focusing on its power product markets of Heavy-Duty Motive (consisting of bus, truck, rail and marine applications), Portable Power, Material Handling and Backup Power, as well as the delivery of Technology Solutions, including engineering services, technology transfer, and the license and sale of its extensive intellectual property portfolio and fundamental knowledge for a variety of fuel cell applications. A fuel cell is an environmentally clean electrochemical device that combines hydrogen fuel with oxygen (from the air) to produce electricity. The hydrogen fuel can be obtained from natural g...

MARA: Marathon Patent Group Analysis and Research Report

2018-08-13 - Asif

Overview Marathon Patent Group was incorporated in the State of Nevada on February 23, 2010 under the name Verve Ventures, Inc. On December 7, 2011, the company changed its name to American Strategic Minerals Corporation and were engaged in exploration and potential development of uranium and vanadium minerals business. In June 2012, the company discontinued its minerals business and began to invest in real estate properties in Southern California. In October 2012, the company discontinued its real estate business when its former CEO joined the firm and the company commenced its IP licensing operations, at which time the Company’s name was changed to Marathon Patent Group, Inc. On November 1, 2017, the company entered into a merger agreement with Global Bit Ventures, Inc. (“GBV”), which is focused on mining digital assets. Marathon Patent Group has since purchased its cryptocurrency mining machines and established a data center in Canada to mine digital assets. Following the me...

ECYT: Endocyte Analysis and Research Report

2018-08-13 - Asif

Business and Organization Endocyte, Inc. is a biopharmaceutical company and leader in developing targeted therapies for the treatment of cancer. The Company uses drug conjugation technology to create novel therapeutics and companion imaging agents for personalized targeted therapies. The agents actively target receptors that are over-expressed on diseased cells relative to healthy cells, such as prostate specific membrane antigen (“PSMA”) in prostate cancer. This targeted approach is designed to safely enable the delivery of highly potent drug payloads. The companion imaging agents are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment. In September 2017, the Company entered into a Development and License Agreement (the “License Agreement”) with ABX advanced biochemical compounds – Biomedizinische Forschungsreagenzien GmbH (“ABX”), pursuant to which the Company acquired exclusive ...